Teleflex to Acquire Biotronik’s Vascular Intervention Business

February 27, 2025—Teleflex Incorporated announced it has entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of Biotronik.

The company stated that the transaction includes an estimated cash payment on closing of approximately €760 million. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by the end of the third quarter of 2025, advised Teleflex.

According to the company, the acquired business will expand the Teleflex Interventional portfolio to include a broad suite of vascular intervention devices such as drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, and balloon catheters. In 2023, approximately 75% of the acquired revenues were generated by coronary interventions and approximately 25% were associated with peripheral interventional procedures, stated Teleflex.

As noted in the press release, the acquired Biotronik Vascular Intervention business includes the following:

• For coronary interventions, the Pantera Lux drug-coated balloon catheter; the PK Papyrus covered coronary stent for acute coronary artery perforations; and the ultrathin Orsiro Mission drug-eluting stent
• For peripheral interventions, the Passeo-18 Lux peripheral drug-coated balloon catheter; the Dynetic-35 balloon-expandable cobalt chromium stent; and the Pulsar-18 T3 self-expanding 4-F stent

Additionally, Teleflex stated that the acquisition will allow it to invest in and expand the clinical trial program for Biotronik’s Freesolve sirolimus-eluting resorbable magnesium scaffold (RMS) technology, including possible pursuit of the United States market.

Teleflex advised that the Freesolve RMS device has received CE Mark approval, indicated for de novo coronary artery lesions. In the BIOMAG-I study, Freesolve RMS demonstrated resorption after 12 months, a target lesion failure rate comparable to contemporary drug-eluting stents, and no definite or probable scaffold thrombosis, noted Teleflex.

The approval and launch of the Freesolve RMS in regions accepting CE Mark was announced by Biotronik in February 2024. In May 2024, Biotronik announced the 2-year follow-up data from BIOMAG-I; and it announced commencement of the European BIOMAG-II study.